Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Rubella and Congenital Rubella Syndrome

Generalities
Agent Rubella virus, genus Rubullovirus, family Togaviridae
Incubation period 14-17 days (range 14-21 days)
Period of transmissibility - 7 days before rash and 4 days after rash onset
- From congenital rubella: infants shed the virus for several months after birth
Reservoir Humans
Modes of transmission - Person-to-person: direct contact with droplets
- Infants with Congenital Rubella Syndrome shed large quantities of virus in their pharyngeal secretions and urine.
- Materno-foetal transmission: 90% of infants born to women infected with rubella during the 1st trimester. The risk of transmission is 10-20% by the 16th week, and rare after the 20th week.
Clinical presentation - Febril maculo-papular rash
- Complications: thrombocytopenia (1/3000), post-infectious encephalitis (1/6000), rarely chronic arthritis
- Congenital Rubella Syndrome: Congenital malformation as deafness, cataracts, microphtalmia, congenital glaucoma, pigmentary retinopathy, nystagmus, microcephaly, meningo-encephalitis, mental retardation, patent ductus arteious, atrial or ventricular septal defects, other congenital heart disease, purpura, hepatosplenomegaly, jaundice, radiolucent bone disease
Resources
Case definitions - MOPH circular no 12 (2013): Acquired Rubella
- MOPH circular no 45 (2007): Congenital Rubella Syndrome
Forms - Rash reporting form
- CRS reporting form
- Rash investigation form
- CRS investigation form
Data - Rubella 2021
- Rubella 2020
- Rubella 2019
- Rubella 2018
- Rubella 2017
- Rubella 2016
- Rubella 2015
 
    ...
    9
    ...
ATC Name B/G Ingredients Dosage Form Price
J01DD01 STOPAREN G Cefotaxime (sodium) - 1g 1g Injectable lyophilised powder for solution+diluent 213,671 L.L
R01AD09 SINOCORT METERED DOSE G Mometasone furoate - 0.05% 0.05% Spray, suspension 419,279 L.L
G04CB01 STERIFINE 5 G Finasteride - 5mg 5mg Tablet, film coated 733,354 L.L
L04AA10 SIROMUNE G Sirolimus - 1mg 1mg Tablet, film coated 18,729,193 L.L
A02BX02 SUCRATE GEL G Sucralfate - 1g 1g Gel 636,981 L.L
L01EX01 SOVIDEX G Sunitinib maleate - 12.5mg 12.5mg Capsule 36,042,560 L.L
G04CB01 STERIBO G Finasteride - 1mg 1mg Tablet, film coated 2,636,619 L.L
L01EX01 SUNITINIB AQVIDA G Sunitinib maleate - 12.5mg 12.5mg Capsule, hard 41,692,397 L.L
L01EX01 SOVIDEX G Sunitinib maleate - 25mg 25mg Capsule 64,804,314 L.L
B05XA03 SERUFLEX SODIUM CHLORIDE 0.9% INJECTION USP G Sodium chloride - 0.9% 0.9% Injectable solution 156,288 L.L
L01EX01 SOVIDEX G Sunitinib maleate - 50mg 50mg Capsule 118,623,323 L.L
N06AB06 SERTINE G Sertraline HCl - 50mg 50mg Tablet, scored 520,899 L.L
B05XA03 SERUFLEX SODIUM CHLORIDE 0.9% INJECTION USP G Sodium chloride - 0.9% 0.9% Injectable solution 165,482 L.L
J01RA SPIRAGYL G Metronidazole - 125mg, Spiramycin - 750,000IU Tablet, scored 474,824 L.L
L01EX01 SUNITINIB AQVIDA G Sunitinib maleate - 50mg 50mg Capsule, hard 151,885,541 L.L
N06AB06 SERTINE G Sertraline HCl - 50mg 50mg Tablet 714,156 L.L
B05XA03 SERUFLEX SODIUM CHLORIDE 0.9% INJECTION, USP G Sodium chloride - 0.9% 0.9% Injectable solution 176,974 L.L
N06AB06 SERTRA TAD G Sertraline HCl - 50mg 50mg Tablet, film coated 689,391 L.L
B05XA03 SERUFLEX SODIUM CHLORIDE 0.9% INJECTION, USP G Sodium chloride - 0.9% 0.9% Injectable solution 163,184 L.L
J01RA SPIRAGYL FORTE G Metronidazole - 250mg, Spiramycin - 1,500,000IU Tablet, scored 474,824 L.L
N06AB06 SERTRALINE BIOGARAN G Sertraline HCl - 50mg 50mg Capsule 520,067 L.L
B05XA03 SERUFLEX SODIUM CHLORIDE 0.9% INJECTION, USP G Sodium chloride - 0.9% 0.9% Injectable solution 156,288 L.L
N06AB06 SOLOTIK G Sertraline HCl - 50mg 50mg Tablet, film coated 428,686 L.L
A03AA04 SPASMINE (Mebeverine HCl 200mg SR) G Mebeverine HCl - 200mg 200mg Capsule, slow release 712,876 L.L
B05XA03 SODIUM CHLORIDE G Sodium chloride - 0.9% 0.9% Injectable solution 4,143,943 L.L
L04AA27 SCLEMOD G Fingolimod Hydrochloride - 0.5mg 0.5mg Capsule 18,264,981 L.L
M01AE03 SOLKET G Ketoprofen Lysine salt - 80mg 80mg Powder for solution 636,981 L.L
B05XA03 SODIUM CHLORIDE G Sodium chloride - 0.9% 0.9% Injectable solution 3,985,356 L.L
L04AA27 SCLEMOD G Fingolimod Hydrochloride - 0.5mg 0.5mg Capsule 17,079,643 L.L
M01AE03 SOLKET INFLAMMATION AND PAIN G Ketoprofen Lysine salt - 0.16% 0.16% Spray 946,065 L.L
    ...
    9
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025